GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Deuterium-substituted L-DOPA   Click here for help

GtoPdb Ligand ID: 8611

Abbreviated name: D3 L-DOPA
Synonyms: DP-102
Compound class: Synthetic organic
Comment: Chronic treatment with a substantially lower dose of deuterium-substituted L-DOPA (D3-L-DOPA), compared with L-DOPA (levodopa) produced equal anti-parkinsonian effects and reduced dyskinesia in 6-OHDA-lesioned rats [2]. This new rat study reports similar effect produced by D3-L-DOPA and selegiline plus L-DOPA, respectively, implying adjuvant MAO-B inhibitor treatment may not be necessary with D3-L-DOPA [1]. This compound was proposed for development by the Michael J Fox foundation but there is no ClinicalTrials.gov entry.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 3
Topological polar surface area 103.78
Molecular weight 197.07
XLogP -2.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OC(=O)C(Cc1ccc(c(c1)O)O)N
Isomeric SMILES OC(=O)[C@](C(c1ccc(c(c1)O)O)([2H])[2H])(N)[2H]
InChI InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1/i3D2,6D
InChI Key WTDRDQBEARUVNC-QZRTVAIESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Malmlöf T, Feltmann K, Konradsson-Geuken Å, Schneider F, Alken RG, Svensson TH, Schilström B. (2015)
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
J Neural Transm, 122 (2): 259-72. [PMID:24906468]
2. Malmlöf T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilström B. (2010)
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.
Exp Neurol, 225 (2): 408-15. [PMID:20659451]